Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting
May 14 2019 - 7:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized
medicine, today announced that it will present results from
multiple studies at the 2019 American Society of Clinical Oncology
(ASCO) annual meeting to be held May 31 to June 4, 2019 in Chicago,
Ill. Abstracts of the company's presentations will be
available at: abstracts.asco.org on May 15 at 5:00 p.m. EDT.
"Myriad is committed to advancing personalized medicine and
providing oncologists with high-quality genetic information to
enhance care for their patients," said Johnathan Lancaster, M.D.,
Ph.D., chief medical officer, Myriad Genetics. "At this
year’s ASCO, we are excited to present multiple studies that
highlight the clinical performance of several of Myriad’s genetic
tests.”
A list of presentation at ASCO 2019 are below. Please
visit Myriad Genetics at booth #5087 to learn more about our
leading portfolio of personalized medicine products. Follow
Myriad on Twitter via @myriadgenetics and keep up to date with ASCO
meeting news and updates by using the hashtag #ASCO19.
Featured Research at 2019 ASCO |
Myriad Product |
Abstract |
Presenting Author |
Presentation/Poster Details |
myRisk® Hereditary Cancer |
Prevalence and penetrance of inherited pathogenic variants in
breast cancer susceptibility genes in the Women’s Health
Initiative |
Allison Kurian |
Poster (#1513)Monday, June 3, 20191:15-4:15pmPoster discussion
4:30-6:00pmPoster Discussion Session: Cancer Prevention, Hereditary
Genetics, and Epidemiology |
Preventive surgery after multiplex genetic panel testing |
Gregory Idos |
Poster (#1525)Monday, June 3, 20191:15-4:15pmPoster Session: Cancer
Prevention, Hereditary Genetics, and Epidemiology |
Hereditary cancer genetic testing among patients with pancreatic
cancer |
Nassim Taherian |
Poster (#4134)Monday, June 3, 20198:00-11:00amPoster Session:
Gastrointestinal (Noncolorectal) Cancer |
|
myChoice® HRD CDx |
TBCRC 030: A randomized phase II study of preoperative cisplatin vs
paclitaxel in TNBC: evaluating the homologous recombination
deficiency (HRD) biomarker |
Erica Mayer |
Podium (#507) Monday, June 3, 2019 9:45 a.m. – 12:45 p.m. Oral
Abstract Session: Breast Cancer – Local/Regional/Adjuvant |
Comparison between whole exome sequencing and single nucleotide
polymorphism-based tumor mutation burden analysis |
Kirsten Timms |
Poster (#2634)Saturday, June 1, 20198:00-11:00amPoster Session:
Developmental Immunotherapy and Tumor Immunobiology |
|
|
About Myriad myRisk® Hereditary
CancerThe Myriad myRisk Hereditary Cancer test uses an
extensive number of sophisticated technologies and proprietary
algorithms to evaluate 35 clinically significant genes associated
with eight hereditary cancer sites including: breast, colon,
ovarian, endometrial, pancreatic, prostate and gastric cancers and
melanoma.
About myChoice® HRD CDxMyriad's myChoice HRD
CDx is the most comprehensive homologous recombination deficiency
test, enabling physicians to identify patients with tumors that
have lost the ability to repair double-stranded DNA breaks,
resulting in increased susceptibility to DNA-damaging drugs such as
platinum drugs or PARP inhibitors. The myChoice HRD test is a
composite of three proprietary technologies (loss of
heterozygosity, telomeric allelic imbalance and large-scale state
transitions). For more information, please visit:
https://myriadmychoice.com/.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: build upon a solid hereditary
cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris,
Foresight and Prequel are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to data being presented for its genetic tests
at the 2019 American Society of Clinical Oncology Annual Meeting
being held May 31- June 4, 2019 in Chicago, Ill; and the Company's
strategic directives under the caption "About Myriad
Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers’
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; the risk that
we may be unable to comply with financial operating covenants under
our credit or lending agreements; the risk that we will be
unable to pay, when due, amounts due under our credit or lending
agreements; and other factors discussed under the heading "Risk
Factors" contained in Item 1A of our most recent Annual Report on
Form 10-K for the fiscal year ended June 30, 2018, which has been
filed with the Securities and Exchange Commission, as well as any
updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. All information in this press release is as of the date
of the release, and Myriad undertakes no duty to update this
information unless required by law.
Media Contact: |
|
Ron Rogers(801) 584-3065rrogers@myriad.com |
|
Investor Contact: |
|
Scott Gleason(801) 584-1143sgleason@myriad.com |
|
|
|
|
|
|
|
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024